Showing results (1-10 of 61) with videos related to
Sort By:
Pageof 7
Current Oncology Reports|September 10, 2008
Management of malignant pleural effusionHongbin Chen, Julie BrahmerCurrent Oncology Reports|June 26, 2007
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?Rosalyn Juergens, Julie BrahmerCancer Chemotherapy and Pharmacology|August 29, 2006
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matterRosalyn Juergens, Julie Brahmer, David EttingerJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel StrategiesAntonio Passaro, Julie Brahmer, Scott Antonia, et al.Survey of Ophthalmology|November 29, 2011
Emerging treatments for choroidal metastasesConnie J Chen, Allison N McCoy, Julie Brahmer, et al.Investigational New Drugs|February 28, 2006
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patientsJing Li, Julie Brahmer, Wells Messersmith, et al.Translational Lung Cancer Research|May 23, 2017
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancerNeil K Taunk, Andreas Rimner, Melissa Culligan, et al.Journal of the National Cancer Institute|December 7, 2006
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitorsJing Li, Mats O Karlsson, Julie Brahmer, et al.Cancer Biology & Therapy|February 22, 2007
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsJing Li, George Cusatis, Julie Brahmer, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 26, 2009
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503Joseph M Amann, Ju-Whei Lee, Heinrich Roder, et al.Pageof 7